An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)

OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This open-label, multicenter, phase I, dose-escalation study included 18 patients (median age:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shin-Wha, Kim, Yong-Man, Kim, Young Tae, Kang, Soon Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391390/
https://www.ncbi.nlm.nih.gov/pubmed/28028994
http://dx.doi.org/10.3802/jgo.2017.28.e26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391390/
https://www.ncbi.nlm.nih.gov/pubmed/28028994
http://dx.doi.org/10.3802/jgo.2017.28.e26

Ejemplares similares